AstraZeneca COPD drug finally gets OK from FDA, inching closer to GSK leader
Almost a year ago, AstraZeneca’s triple-drug combination for chronic obstructive pulmonary disease was shot down with an FDA complete response letter. But on Friday, it finally received the green light.
The UK pharma giant has received approval for its Breztri Aerosphere, formerly dubbed PT010, culminating the drug’s bumpy regulatory journey in a win. Now, AstraZeneca can challenge the leader in the area — GlaxoSmithKline’s Trelegy — without obstacle.